Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgkin’s Lymphoma
CHICAGO–(BUSINESS WIRE)–#AIpowered–Nucleai, an AI-powered spatial biology company with a mission to transform drug development and…
Getting Value From AI Takes More Than Buying The Tools
Cerence AI and Geely Advance Human-Machine Interaction Through Robotics Technology Services Partnership